Tvardi Therapeutics, Inc. (NASDAQ:TVRD) Receives $55.50 Average Price Target from Brokerages

Tvardi Therapeutics, Inc. (NASDAQ:TVRD) has received a consensus recommendation of “Moderate Buy” from the eight ratings firms that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation, three have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $55.50.

Several research analysts have weighed in on TVRD shares. Lucid Cap Mkts upgraded Tvardi Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 4th. Weiss Ratings reissued a “sell (e)” rating on shares of Tvardi Therapeutics in a report on Monday, December 29th. Finally, Wall Street Zen raised shares of Tvardi Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, February 7th.

Tvardi Therapeutics Stock Up 1.1%

NASDAQ:TVRD opened at $3.82 on Thursday. The business’s 50-day simple moving average is $4.19 and its two-hundred day simple moving average is $14.81. Tvardi Therapeutics has a 52 week low of $3.50 and a 52 week high of $43.65. The stock has a market cap of $35.84 million, a PE ratio of -0.40 and a beta of 0.14.

Tvardi Therapeutics (NASDAQ:TVRD) last released its earnings results on Thursday, November 13th. The company reported ($0.59) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.83) by $0.24.

Hedge Funds Weigh In On Tvardi Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. 683 Capital Management LLC bought a new position in shares of Tvardi Therapeutics during the 2nd quarter valued at approximately $4,107,000. Slate Path Capital LP bought a new position in Tvardi Therapeutics during the second quarter valued at $16,427,000. Geode Capital Management LLC lifted its position in Tvardi Therapeutics by 6.2% during the fourth quarter. Geode Capital Management LLC now owns 157,133 shares of the company’s stock valued at $676,000 after purchasing an additional 9,214 shares during the last quarter. Marshall Wace LLP purchased a new position in shares of Tvardi Therapeutics in the 2nd quarter worth $583,000. Finally, Bank of America Corp DE bought a new stake in shares of Tvardi Therapeutics in the 2nd quarter worth about $399,000. 44.66% of the stock is owned by institutional investors.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.